Breezula, A Clinical Stage Topical Anti-Androgen, Promotes Dermal Papilla Inductivity And Reduces IL-6 Secretion In Balding Skin Samples Ex Vivo

    July 2025 in “ Journal of Investigative Dermatology ”
    A. Le Riche, P. Pallavi, Mara Gerloni, Gordon Alton, J. Edelkamp, Marta Bertolini
    The study investigates the efficacy of Breezula® (clascoterone 5% solution) compared to Minoxidil (5%) in treating male pattern hair loss (MPHL) using scalp biopsies from 5 patients. Both treatments enhanced alkaline phosphatase (AP) activity and hair matrix (HM) keratinocyte proliferation, which are associated with hair growth. Notably, Breezula® also reduced IL-6 secretion, a hair growth inhibitor, suggesting it may be more potent than Minoxidil in promoting hair growth. These findings indicate that Breezula® could restore dermal papilla (DP) inductivity and support hair growth, meriting further research.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 335 results

      community Cosmo Pharma Lists Breezula Phase 3 Trial on ClinicalTrials.gov

      in Research/Science  25 upvotes 2 years ago
      A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

      community Minoxidil alone, 4 months consistent usage

      in Is this regrowth?  515 upvotes 5 months ago
      Minoxidil 5% foam was used twice daily for 4 months, resulting in visible hair regrowth. Users discussed adding finasteride for better long-term results, with concerns about its side effects and alternatives like breezula and clascoterone.

      community Chat is this real? Compound called clascoterone

      in Research/Science  580 upvotes 2 months ago
      Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

    Related Research

    7 / 7 results